Dodecanol

Dodecanol

SCHEMBL2369293

CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC.CCCCCCCCCCCCO

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.74
NAAA Q02083 1/20 0.62
PRSS1 P07477 1/20 0.61
PRSS2 P07478 1/20 0.61
PRSS3 P35030 1/20 0.61
DNM1 Q05193 1/20 0.61
HTR2C P28335 1/20 0.59
PAM P19021 2/20 0.56
ACHE P22303 6/20 0.54
KDM4E B2RXH2 1/20 0.54
DUSP3 P51452 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490307 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL2518708 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL20067021 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL21800953 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL20740271 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL2802141 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL2145746 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL3443790 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL8981714 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3
SCHEMBL17335289 1.00 DGKA (0.74) DGKANAAAPRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2538920-A1 EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES Precision Dermatology, Inc. (US) 2013-01-02 EP disclosed
WO-2011106026-A1 EMOLLIENT FOAMS FOR TREATMENT OF DERMATOSES PRECISION DERMATOLOGY, INC. (US) 2011-09-01 WO disclosed